Showing papers on "Female Sexual Arousal Disorder published in 2009"
TL;DR: Although women with FSAD had low ratings of sexual desire on the FSFI, they could recall recent experiences of desire that did not differ from the control group, and most women acknowledged emotional connection as most important.
Abstract: There is controversy about the nature of women's sexual desire. The aim was to explore narrative descriptions of sexual desire among mid-aged women in hopes of clarifying how women define and experience sexual desire, and how these might differ among women with and without female sexual arousal disorder (FSAD). Mid-aged women without (age: M = 45, n = 12) and with (age: M = 55, n = 10) FSAD took part in in-depth interviews that invited them to share personal stories of sexual desire. Women also completed the Brief Index of Sexual Functioning and the Female Sexual Function Index (FSFI). Women in both groups described sexual desire in genital, non-genital physical, and in cognitive-emotional terms. Although women with FSAD had low ratings of sexual desire on the FSFI, they could recall recent experiences of desire that did not differ from the control group. Women identified a number of triggers of desire including touch, memories, and partner's responses--the latter of which acted as both a trigger and an inhibitor. Women in the control group were more likely to express conflation about the distinction between desire and arousal. Among the different "objects" of women's desire, most women acknowledged emotional connection as most important.
154 citations
TL;DR: Women seeking bariatric surgery are clearly a population with substantial sexual function impairment, with 60% of participants reporting FSD, and these findings highlight the need to initiate routine assessment of sexual functioning in this population and examine whether the weight loss afterbariatric surgery contributes to a reversal of FSD.
66 citations
TL;DR: The effects of estrogen on increasing genital blood flow and smooth muscle relaxation have been attributed mostly to regulation of eNOS, however, the exact mechanisms ofeNOS regulation in female genital tract structures and the molecular basis for the eNos defect with aging and vascular diseases warrant further investigation.
60 citations
TL;DR: It is suggested that FSAD with and without distress be considered two different disorders, with the distressed group showing more long-term signs of psychosexual impairment.
53 citations
TL;DR: A variety of treatment modalities exist, though current research has not yet provided Food and Drug Administration approved therapies for sexual disorders in women.
43 citations
TL;DR: The trials show that sildenafil citrate is moderately effective in the treatment of FSAD, and may also be effective in women with FSAD secondary to multiple sclerosis, diabetes or antidepressant use; however, more trials in these patient populations are required to confirm these findings.
Abstract: Female sexual arousal disorder (FSAD) is a common disorder encountered in clinical practice, with self-reported arousal difficulties reported in up to 26% of American women. Various oral therapies for FSAD have been studied, including sildenafil citrate, a phosphodiesterase inhibitor that is currently used to treat male erectile dysfunction. In vitro studies of sildenafil citrate have demonstrated smooth-muscle relaxation in clitoral tissue, and phosphodiesterase type-5 has been shown to be present in vaginal, clitoral and labial smooth muscle; these findings have led to theories that sildenafil citrate might be successful for treating FSAD. This Review discusses the data from clinical trials that have assessed sildenafil citrate for the treatment of FSAD; the trials show that sildenafil citrate is moderately effective. Sildenafil citrate may also be effective in women with FSAD secondary to multiple sclerosis, diabetes or antidepressant use; however, more trials in these patient populations are required to confirm these findings.
42 citations
TL;DR: The SCS and the SRS are reliable and valid instruments in men with PE or ED and in women with FSAD and may be used either as stand-alone measures or in conjunction with the SQOL to provide a complete assessment of sexual quality of life.
26 citations
TL;DR: There is no evidence to support the belief that women who meet criteria for a diagnosis of PGAD are "hypersexual," and their overall sexual functioning falls within the normal range and is significantly better than that of women diagnosed with FSAD.
26 citations
TL;DR: The effects of heightened sympathetic nervous system activity via laboratory-induced hyperventilation (LIH) on subjective and physiological sexual arousal were examined in a heterogeneous group of women with Sexual Arousal Disorder as well as across subtypes of SAD, in comparison to a control group of Women without sexual difficulties.
Abstract: The effects of heightened sympathetic nervous system (SNS) activity via laboratory-induced hyperventilation (LIH) on subjective and physiological sexual arousal were examined in a heterogeneous group of women with Sexual Arousal Disorder (SAD; n = 60), as well as across subtypes of SAD, in comparison to a control group of women without sexual difficulties (n = 42). Participants took part in 2 min of rapid breathing, a technique previously found to increase SNS activity, immediately prior to viewing erotic stimuli. Physiological arousal (i.e., vaginal pulse amplitude; VPA) was measured via the vaginal photoplethysmograph and subjective arousal was measured via self-report questionnaires. LIH differentiated women with SAD from those in the control group, with LIH increasing VPA in the latter, but having no significant effect in the heterogeneous SAD group. However, among subtypes of SAD, LIH differentiated women with genital (n = 16) and subjective (n = 16) subtypes of SAD from women with combined SAD (n = 28) and women without sexual difficulties. Specifically, women in the control group and those with combined SAD had a significant increase in VPA whereas women with genital or subjective SAD had a significant decrease in VPA following LIH. There was no significant effect of LIH on any self-report measure of sexual arousal following erotic stimuli. Implications of the results for the conceptualization, diagnosis, and treatment of SAD are discussed.
11 citations
TL;DR: Assessments and treatment options for female sexual arousal disorder and hypoactive sexual desire disorder are presented along with a case example.
Abstract: Female sexual arousal disorder (FSAD) is a common condition in women that frequently copresents with hypoactive sexual desire disorder (HSDD). Although some of the principles and practice within clinical management of these 2 conditions is similar, it is essential that as accurate a diagnosis and assessment as possible is made to clarify the thinking and formulation of the problem(s) for the clinician, woman, or her partner. The clinician needs to have a wide range of tools and knowledge in order to integrate the physical, relational, and psychological interventions that are needed for the individual to understand the diagnosis and what options are available. Various assessments and treatment options are presented along with a case example.
9 citations
TL;DR: It is important to note that diagnosing an isolated dysfunction like female sexual arousal disorder is often difficult due to the dynamic nature of a woman's sexual response, so the use of a treatment, platform, however should be the foundation of the treatment.
Abstract: The study of sexual health is not a new concept in western medicine. However, focusing on women's sexual health and specifically on female sexual dysfunction has become a new trend. What has followed has been a genuine attempt by the medical community to define normal sexual health for women, as well as female sexual dysfunction and to develop efficacious treatment protocols for women with sexual dysfunction. Despite having its own definition, it is important to note that diagnosing an isolated dysfunction like female sexual arousal disorder is often difficult due to the dynamic nature of a woman's sexual response. The use of a treatment, platform, however should be the foundation of the treatment.
Journal Article•
TL;DR: Female sexual arousal disorder (FSAD) is a subtype of female sexual dysfunction that occurs when a woman experiences distress due to the inability to attain or maintain adequate vaginal lubrication.
Abstract: Female sexual arousal disorder (FSAD) is a subtype of female sexual dysfunction. It occurs when a woman experiences distress due to the inability to attain or maintain adequate vaginal lubrication. Common causes of FSAD include a lack of vaginal estrogen, arterial insufficiency, tactile insensitivity, or relationship conflict.
01 Jan 2009
TL;DR: The SCS and the SRS are reliable and valid instruments in men with PE or ED and in women with FSAD and may be used either as stand-alone measures or in conjunction with the SQOL to provide a complete assessment of sexual quality of life.
Abstract: Introduction. The Sexual Confidence Scale (SCS) and the Sexual Relationship Scale (SRS) are two new measures designed for use by men and women across sexual dysfunction groups. The SCS assesses how confident an individual feels as a sexual partner, while the SRS assesses feelings that an individual has about their sexual relationship with their partner. Aim. To conduct item reduction and psychometric validation of the SCS and SRS instruments. Methods. To validate the new measures, 104 men with premature ejaculation (PE), 101 men with erectile dysfunc- tion (ED) and 106 women with female sexual arousal disorder (FSAD) took part in the study. One hundred and one males and 53 females without sexual dysfunction also completed the measures. Main Outcome Measures. The internal consistency, convergent, and discriminant validity, test-retest reliability and known-groups validity of the instruments were assessed. Results. The number of items in each scale was reduced following standard item reduction analyses and reference to the conceptual framework. Factor analysis confirmed a one-factor solution for the SCS and a two-factor solution for the SRS. Internal consistency was good, with cronbach's alpha 0.7 across the groups for both the SCS and SRS. Excellent test-retest reliability and ability to discriminate between men and women with and without sexual dysfunction were also demonstrated for both scales. Correlations with the Sexual Quality of Life Questionnaire (SQOL) ranged from 0.48 to 0.80 indicating good convergent validity. Conclusions. The SCS and the SRS are reliable and valid instruments in men with PE or ED and in women with FSAD. These modules may be used either as stand-alone measures or, preferably, in conjunction with the SQOL to provide a complete assessment of sexual quality of life. Abraham L, Symonds T, May K, Althof SE, Hallam-Jones R, and Rosen RC. Psychometric validation of gender nonspecific sexual confidence and sexual relationship scales in men and women. J Sex Med 2009;6:2244-2254.
01 Aug 2009
Patent•
14 Jan 2009
TL;DR: In this paper, the authors present methods of treating sexual dysfunction using nebivolol, or a pharmaceutically acceptable salt thereof, alone or in combination with a PDE-5 inhibitor, such as sildenafil citrate.
Abstract: The present invention provides methods of treating sexual dysfunction. The methods include administering an effective amount of nebivolol, or a pharmaceutically acceptable salt thereof, alone or in combination with a second active agent e.g. a PDE-5 inhibitor, such as sildenafil citrate. The methods of the present invention are particularly suited to the treatment of erectile dysfunction and female sexual arousal disorder.